According to the Jinghua Pharmaceutical announcement, the company's Sun Company, Jinghua Pharmaceutical Group, Nantong Co., Ltd. obtained the approval and issuance of the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for salfiamide mesylate from the State Drug Administration. Salfamide mesylate is an anti-Parkinson's drug. This approval indicates that Nantong Company is eligible for domestic marketing and supply of this API. Its registration status changed to “A” at the same time, and it can be supplied to domestic pharmaceutical companies for formulation declaration and production use. This approval will enrich the company's API product pipeline and enhance market competitiveness in the field of specialty APIs. There is uncertainty about actual sales and operating efficiency in the future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.